-
Approximately half of all cases of heart failure occur in the context of normal systolic function (heart failure with preserved ejection fraction [HFPEF]) and the number of cases is projected to rise as the population ages.
-
Perioperative cardiac events are the leading cause of surgical mortality. Thus, there has been considerable interest in predicting which patients are at highest risk.
-
This report is from the ARISTOTLE trial, which was just reported at the recent European Society of Cardiology meeting in Paris. Apixaban is a new direct oral factor Xa inhibitor with a favorable pharmacokinetic profile.
-
Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
-
FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
The use of aspirin for the primary prevention of cardiovascular (CV) disease remains controversial. In this publication, Bartolucci updates his 2006 meta-analysis by adding three new trials to the six previous ones.
-
-
The benefits of cardiac rehabilitation following myocardial infarction (MI) are well known. However, whether these benefits are also seen in ambulant community-based patients who undergo percutaneous coronary intervention (PCI) is not known.
-
Percutaneous transcatheter aortic valve implantation (TAVI) is an emerging technique for the treatment of aortic stenosis (AS). By this method, a bioprosthetic valve (bovine pericardium) attached to a stent can be deployed in the aortic valve position via a catheter delivery system inserted through either the femoral artery or via the apex of the left ventricle. This technique is available in Europe and is being considered by the FDA for release in the United States.